

# Chlamydia - Pipeline Insight, 2021

https://marketpublishers.com/r/C1825F7A3AF5EN.html

Date: July 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: C1825F7A3AF5EN

### **Abstracts**

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Chlamydia – Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chlamydia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Chlamydia Understanding

Chlamydia: Overview

Chlamydia is a sexually transmitted infection (STI) caused by a bacteria called chlamydia trachomatis. It can cause serious, permanent damage to a woman's reproductive system. Chlamydia is usually passed on through unprotected vaginal, anal or oral sex. Chlamydia can be passed on through genital contact.

Signs of chlamydia in women include:

increase in vaginal discharge

pain or burning when urinating (peeing)



pain during sex and/or bleeding after sex

pain in the lower stomach - especially when having sex

bleeding between periods and/or heavier periods.

Signs of chlamydia in men include:

white, cloudy or watery discharge from the penis

pain or burning when urinating

pain and/or swelling in the testicles.

Getting tested for chlamydia is easy and doesn't hurt. A healthcare professional will ask for a urine (pee) sample and/or take a swab from the area that might be infected. This is usually the lower part of the womb (cervix) or the vagina for women, and the tip of the penis (urethra) for men. Azithromycin is an antibiotic usually prescribed in a single, large dose. Doxycycline is an antibiotic that must be taken twice per day for about one week. Other antibiotics may also be given.

'Chlamydia - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chlamydia pipeline landscape is provided which includes the disease overview and Chlamydia treatment guidelines. The assessment part of the report embraces, in depth Chlamydia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chlamydia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

#### Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chlamydia R&D. The therapies under development are focused on novel approaches to treat/improve Chlamydia.



### Chlamydia Emerging Drugs Chapters

This segment of the Chlamydia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chlamydia Emerging Drugs

EVO100: Evofem

EVO100 vaginal gel is designed to reduce certain vaginal infections by: Balancing vaginal pH, thereby maintaining healthy vaginal flora and creating an environment that is detrimental to the growth and proliferation of harmful bacteria and using a different mechanism of action that may help to address drug resistance concerns. In October 2020, Evofem initiated EVOGUARD, a pivotal Phase III clinical trial to evaluate the safety and efficacy of EVO100 for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. Top-line results are expected in 2022.

Chlamydia Vaccine Candidate: Eurocine Vaccines AB

Eurocine Vaccines AB is developing a Chlamydia Vaccine Candidate. They have successfully identified sections of the MOMP (Major Outer Membrane Protein) in the bacterium Chlamydia trachomatis – sequences that can be used to stimulate an immune response. The specially designed protein chains are essential for the creation of the vaccine and are patent protected. Eurocine Vaccines entered into a collaboration and license agreement with Spixia Biotechnology for the development and commercialization of Chlamydia vaccines. Under the agreement, Eurocine Vaccines receives an exclusive right to develop, manufacture and commercialize vaccine candidates against Chlamydia based on vaccine antigens that Spixia Biotechnology has developed.

Further product details are provided in the report......

Chlamydia: Therapeutic Assessment



This segment of the report provides insights about the different Chlamydia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Chlamydia

There are approx. 10+ key companies which are developing the therapies for Chlamydia. The companies which have their Chlamydia drug candidates in the most advanced stage, i.e. Phase III include, Evofem.

**Phases** 

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration


Chlamydia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous






licensing along with a thorough therapeutic assessment of emerging Chlamydia drugs.

Chlamydia Report Insights







What are the clinical studies going on for Chlamydia and their status?

What are the key designations that have been granted to the emerging drugs?



## **Contents**

Introduction

**Executive Summary** 

Chlamydia: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

EVO100: Evofem

**Product Description** 

Research and Development

**Product Development Activities** 

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Drug Name: Company Name

**Product Description** 

Research and Development

**Product Development Activities** 

Drug profiles in the detailed report.....

Preclinical stage products (Phase I/II)

Comparative Analysis

Chlamydia Vaccine Candidate: Eurocine Vaccines AB

**Product Description** 

Research and Development

**Product Development Activities** 



Drug profiles in the detailed report.....

**Inactive Products** 

Comparative Analysis

Chlamydia Key Companies

Chlamydia Key Products

Chlamydia- Unmet Needs

Chlamydia- Market Drivers and Barriers

Chlamydia- Future Perspectives and Conclusion

Chlamydia Analyst Views

Chlamydia Key Companies

Appendix



# **List Of Tables**

#### LIST OF TABLES

Table 1 T	otal Produ	icts for C	Chlamydia	a
-----------	------------	------------	-----------	---

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

**Table 12 Inactive Products** 



# **List Of Figures**

#### LIST OF FIGURES

Figure 1	Total	<b>Products</b>	for	Chlam	≀dia
----------	-------	-----------------	-----	-------	------

- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products



## I would like to order

Product name: Chlamydia - Pipeline Insight, 2021

Product link: <a href="https://marketpublishers.com/r/C1825F7A3AF5EN.html">https://marketpublishers.com/r/C1825F7A3AF5EN.html</a>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

# **Payment**

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <a href="https://marketpublishers.com/r/C1825F7A3AF5EN.html">https://marketpublishers.com/r/C1825F7A3AF5EN.html</a>